The results of our previous study 12 showed that trehalose-a nonreducing disaccharide of sugar that is naturally present in many kinds of organisms-can provide optimal protection of adipose tissue as a stand-alone CPA in an optimal concentration during cryopreservation. 12 If trehalose can serve as a single CPA for cryopreservation of adipose tissue, this would potentially simplify the procedure for cryopreservation of human adipose tissue, given that it does not need to be removed from previously cryopreserved adipose tissue after thawing, because of its nontoxic nature. Therefore, the purpose of the present study was to evaluate the efficacy of trehalose as a single CPA in its optimal concentration, as established in our previously published in vitro study, for cryopreservation of human fat grafts in a well-established nude mouse animal model for preparation of a possible clinical trial of repeated autologous fat grafting.
METHODS

Collection and Processing of Adipose Aspirates
Adipose aspirates were obtained from a healthy adult Caucasian woman who underwent conventional liposuction of her abdomen for cosmetic contour improvement. The study was approved by the university's institutional review board. Before the procedure, the abdomen of the patient was infiltrated with 1 L of lactated Ringer's solution, 30 mL of 2% lidocaine, and 1 mL of epinephrine. The adipose aspirates in this study were harvested with Byron aspiration cannulas (3 or 4 mm in diameter) and a conventional liposuction machine (Byron Medical, Tucson, Arizona). About 150 mL of adipose aspirates were collected into a sterile bottle at the time of the liposuction and the bottle was transferred to the laboratory immediately for centrifugation at 50 g for 10 minutes on a large-capacity centrifuge (Mistral 3000i, Curtin Matheson Scientific Inc., Houston, Texas), as previously described. 1 After centrifugation, the middle layer of adipose aspirates, which usually contains more viable adipocytes, was then pipetted from the large test tube. From this layer, each 15 mL of adipose aspirate was taken for the study, according to our research protocol.
Experimental Design
After centrifugation, adipose aspirates from the patient were randomized into the following three groups: the control group, the fresh adipose aspirates without preservation; the cryopreservation group 1, in which adipose aspirates were cryopreserved with our previously selected combination of DMSO and trehalose as CPA 1, 11 ; and the cryopreservation group 2, in which adipose aspirates were cryopreserved with only trehalose as a CPA but in its optimal concentration (0.35M). 12 
Preparation of CPA Solutions
Trehalose and DMSO (Sigma, St. Louis, Missouri) were the CPA included in this study. Both solutions in double concentration were previously made, filtered for sterilization (0.22-µm filter), and stored as a stock solution at 4°C. Before freezing, the double-concentrated solutions were freshly diluted with 1:1 volume of CPA mixture and adipose tissue to reach the final designed concentration (for the cryopreservation group 1, a combination 0.5M of DMSO and 0.2M of trehalose; for the cryopreservation group 2, 0.35M of trehalose) 30 minutes before cryopreservation.
Cryopreservation Procedure
The detailed freezing method was the same as in our previous study. 1, 11, 13 Briefly, a total of 10 mL adipose aspirates were mixed with 10 mL of different CPA for each cryopreserved group in a vial and the mixture was placed at room temperature for 10 minutes. The vial was then put into a chamber of a programmed freezing machine (CRYO-10, Series III; Planer, Middlesex, UK). In this machine, the freezing system was set up for a slow cooling rate of 1°C per minute, from 22°C to -30°C, without artificially induced ice formation. After the temperature within the vial reached -30°C and was held for another 10 minutes at that temperature, it was transferred to a liquid nitrogen (-196°C) tank for long-term preservation. All cryopreserved adipose aspirates, once they became equilibrated in liquid nitrogen for 20 minutes, were considered to have undergone the equivalent "long-term" preservation and were ready for thawing.
For thawing, each vial containing cryopreserved adipose aspirates was taken from the liquid nitrogen tank and placed at room temperature for two minutes, to allow the liquid nitrogen to vapor out of the vial. The vial was then directly dropped into a stirred 37°C water bath until the frozen adipose aspirates were thoroughly thawed. For the cryopreservation group 1, the DMSO within the previously cryopreserved adipose aspirates was removed with a series of subsequent dilutions and centrifugations. For the control group, after centrifugation, 10 mL of adipose aspirates were mixed with 10 mL of normal saline and placed at room temperature. All fresh or cryopreserved adipose aspirates were then ready to be injected into nude mice.
Administration of Cryopreserved Adipose Aspirates
Six-week-old CD-1 male nude mice (N = 60) were subjected to this study and randomized into three groups (n = 20 per group). All nude mice were kept in the pathogen-free animal-breeding facility under laminar airflow and fed with standard laboratory chow and water. Each nude mouse was anesthetized by inhalation of isoflurane before injection. After the back of the scalp was cleaned with an alcohol swab, 0.5 mL of fresh or cryopreserved adipose aspirates was injected into the posterior scalp via a 1-mL syringe connected with a 16-gauge needle, according to our experimental protocol (fresh adipose aspirates for the control group, adipose aspirates after cryopreservation with the combination of CPA for cryopreservation group 1, and adipose aspirates after cryopreservation with trehalose as a single CPA for cryopreservation group 2). See Figures 1 and 2 . The exact preinjection volume of the adipose aspirates was recorded and the exact weight measured with a balance (Mettler PM100, Mettler Inc., Hightown, New Jersey). A total of 20 nude mice were injected in each group. Each animal was carefully observed daily for gross inspection of the maintained volume of the injected fat grafts over their posterior scalps for up to eight weeks.
Assessments
At the end of eight weeks after in vivo transplantation of adipose aspirates, each animal that survived the study was euthanized in a carbon dioxide chamber. An encapsulated fat graft over the back of the mouse's scalp was surgically removed for the following assessments. The final volume and weight of the maintained fat grafts were calculated at the end point of the study.
Volume and weight measurement. An encapsulated fat graft harvested from each animal was measured for volume (in cubic centimeters) by a volume displacement test. Briefly, the graft was placed into an empty 3-mL syringe; the syringe was then filled with normal saline, up to 1 mL. Once the level of the solution became stable in an upright position, the graft was gently removed with a pair of small forceps. The volume of the graft in cubic centimeters was calculated by 1 mL minus the reading (in cubic centimeters) over the syringe without the graft (see Figure 3) . The volume was recorded and compared with the original volume of each animal before injection. An encapsulated fat graft harvested from each animal was also weighed with a fine analytical balance (Mettler PM100; Mettler Inc.). The weight of each fat graft (in grams) was recorded and compared with the original weight of each animal before injection.
Histological examination. Each encapsulated fat graft, once its weight and volume were measured, was immediately fixed in 10% buffered formalin, embedded in paraffin, and sectioned at 5 µm. It was then processed through graded alcohols and xylene and stained with hematoxylin and eosin. All slides were examined by the same experienced pathologist in a single-blinded fashion for evidence of architectural disruption, adipocyte degeneration, fibrosis, or necrosis. 
Statistical Analysis
All data in this study were expressed as mean ± standard deviation. A two-tailed t test was performed to assess the results among three groups. A P value less than .05 was considered statistically significant. Furthermore, the Bonferroni correction was applied to control the type I error and to modify and ensure the accuracy of statistical analyses.
RESULTS
During the eight-week study period, each nude mouse was observed daily. If an animal had an abnormal behavior or sustained any injury, we euthanized it: Five animals-one from the control group, three from group 1, and one from group 2-died during the study and were thus excluded. The remaining 55 animals were healthy and survived to the end of the study.
At the end of eight weeks, after euthanization and harvesting of the retained fat grafts, we found that the grafts were well encapsulated in all three groups. Various degrees of absorption were found in all three groups-even in the control group. However, the injected fat grafts were able to survive in this animal model during the study.
The original volume of injected fat grafts was 0.51 ± 0.01 mL in the control group, 0.52 ± 0.02 mL in group 1, and 0.51 ± 0.02 mL in group 2. The retained volume at eight weeks was 0.28 ± 0.06 mL in the control group, 0.24 ± 0.08 mL in group 1, and 0.21 ± 0.06 mL in group 2. When these data were expressed as the percentage of the injected fat grafts maintained (retained volume divided by original volume × 100%), there was significantly higher maintained volume in the control group (55.5% ± 11.7%) compared to group 1 (46.1% ± 14.4%, P < .05) or group 2 (38.2% ± 10.5%, P < .01). However, there was no significant difference in the maintained volume between the two cryopreservation groups (46.1% ± 14.4% versus 38.2% ± 10.5%, ns) ( Figure 4) .
The original weight of injected fat grafts was 0.49 ± 0.01 g in the control group, 0.52 ± 0.02 g in group 1, and 0.51 ± 0.02 g in group 2. The retained weight at eight weeks was 0.24 ± 0.04 g in the control group, 0.20 ± 0.07 g in group 1, and 0.18 ± 0.06 g in group 2. When these data were expressed as the percentage of the injected fat grafts maintained (retained weight divided by original weight × 100%), there was a significantly higher maintained weight in the control group (50.7% ± 9.3%) compared to both group 1 (38.9% ± 14.7%, P < .01) and group 2 (34.1% ± 12.1%, P < .01). However, there was no significant difference of the maintained weight between the two cryopreservation groups (38.9% ± 14.7% versus 34.1% ± 12.1%, ns) ( Figure 5 ).
Histologically, a maintained adipose tissue structure within an encapsulated fibrous capsule was primarily found in all three groups. The basic architecture of fragmental adipose tissue was maintained in all three groups, except that some tissue shrinkage was found in both cryopreservation groups ( Figure 6 ). However, there was no evidence of fatty tissue degeneration or necrosis in any of the three groups.
DISCUSSION
The present in vivo study was conducted on the basis of findings from our previous in vitro study. 12 In that study, trehalose served as a single CPA at the concentration of 0.35M and was proven to provide adequate protection of adipose tissue during cryopreservation. If trehalose (in its optimal concentration) could effectively be used in a subsequent in vivo study with a similar finding, the toxic effects of a commonly-used CPA such as DMSO after thawing at room temperature could be eliminated for cryopreservation of adipose tissue. In addition, no additional dilutions and centrifugations would be needed to remove DMSO from the previously cryopreserved fat grafts; thus, further damage to cryopreserved fat grafts could be avoided.
In the present study, previously cryopreserved adipose aspirates were treated with CPA of either trehalose (in 0.35M) or a combination of DMSO (in 0.5M) and trehalose (in 0.2M). The CPA was injected into an established nude Figure 4 . Results of maintained volume, expressed as percentage of pretreatment volume (maintained volume divided by preinjection volume × 100%), at eight weeks after in vivo administration of fresh or cryopreserved adipose aspirates. CPA, cryoprotective agents. *Versus fresh control, P < .01. Versus combined CPA, not significant. Figure 5 . Results of maintained weight, expressed as percentage of pretreatment weight (maintained weight divided by preinjection weight × 100%), at eight weeks after in vivo administration of fresh or cryopreserved adipose aspirates. CPA, cryoprotective agents. *Versus fresh control, P < .01. Versus combined CPA, not significant. mouse model. Eight weeks after in vivo transplantation, both groups had similar percentages of the maintained volume and weight of transplanted fat grafts. Histologically, the basic structure of fragmental adipose tissue was adequately maintained. Given that, first, the combination of DMSO (in 0.5M) and trehalose (in 0.2M) is considered the best option as CPA for cryopreservation of adipose aspirates (based on our previous in vitro studies) and, second, the findings from the present in vivo study have shown a comparable result to that of trehalose (in 0.35M) as a stand-alone CPA, 1, 11 we believe that trehalose (in 0.35M) can be effectively used as a CPA for cryopreservation of human fat grafts with our established freezing and thawing protocol. However, the results from either cryopreservation group are still less satisfactory than those from the control group. This may be true not only for adipose tissue but for other types of tissues after optimal cryopreservation. 1, [13] [14] [15] Clearly, further refinements are needed to improve the viability of adipose tissue during cryopreservation.
Theoretically, individual cells or tissue may have their own unique optimal freezing and thawing conditions to achieve maximum survival after undergoing cryopreservation. Based on our previous studies on cryopreservation of human adipose tissue, slow controlled cooling at the rate of 1°C to 2°C per minute and fast warming at the rate of 30°C to 50°C per minute are suitable for cryopreservation of human adipose tissue. 1, 6, [11] [12] [13] In addition, a predetermined end temperature of -30°C also preserves some features of adipose tissue because a mature fatty cell contains little water inside the cell. Thus, adipose tissue may not need to be frozen to a low temperature (ie, lower than -30°C).
Furthermore, the temperature requirement for freezing adipose tissue is found to be quite different from that of other cells or tissues. 14, 15 Because trehalose can stabilize the cell membrane and improve cell or tissue survival during cryopreservation or freeze-drying procedures, [15] [16] [17] [18] trehalose in its optimal concentration may provide equivalent protection of adipose tissue compared to that of DMSO and trehalose in their optimal combination, as proposed from our early studies with the same freezing and thawing protocol. 1, 6, 11, 13 Adding CPA to cells, tissues, or even organs before freezing is an important step during cryopreservation. [1] [2] [3] [4] [5] Some authors recommend storing fat in a commercial refrigerator (-20°C) without adding CPA and then commencing a freezing and thawing procedure. 19, 20 However, our preliminary studies showed a poor result of adipose tissue after this kind of "cryopreservation,"
21 thereby indicating that a formal cryopreservation is required (ie, adding CPA and performing the freezing and thawing procedure).
A more recent study showed that freezing adipose tissue in saline at -20°C for only 24 hours results in morphologic changes in the tissue and affects the potential viability of adipose tissue to synthesize vascular endothelial growth factor. 22 Of course, such a temperature (-20°C) is not optimal for the storage of adipose tissue. It is well known that for long-term preservation of cells and tissues, liquid nitrogen temperature (-196°C ) is an ideal condition. Figure 6 . Routine histology of the fat grafts at eight weeks after in vivo administration of fresh or cryopreserved adipose aspirates (hematoxylin and eosin staining; original magnification, 200×). A maintained adipose tissue structure within an encapsulated fibrous capsule was primarily seen in all three groups. The basic architecture of fragmental adipose tissue was maintained in all three groups, except that some tissue shrinkage was found in both cryopreservation groups: A, control group; B, cryopreservation group 1; C, cryopreservation group 2.
Once again, trehalose is a nonreducing disaccharide of glucose and can be found at high concentration in a variety of organisms. It is not toxic to tissues at either low or normal temperature, and it is safe in humans for cryopreservation of adipose tissue. Because trehalose is a form of glucose and no adverse effects have been reported or observed in vivo, it may not be subject to any regulatory concerns if applied clinically for cryopreservation of living tissues such as fat.
CONCLUSIONS
The results from the present in vivo study confirm the findings from our previous in vitro study that trehalose, in its optimal concentration, appears to provide adequate protection of adipose tissue during cryopreservation. Our modified cryopreservation protocol described in this study provides an equivocal outcome compared with the protocol previously developed. 1, 6, 11, 13 Although refinements may be needed for this newly developed protocol, our modified protocol for cryopreservation of adipose tissue developed from our previous in vitro study and used in this in vivo study has possible clinical application in patients for banking of their fat grafts. A preliminary clinical trial will be considered after a proper institutional approval.
